ADVBHealthcare · Diagnostics & ResearchADVB Stock Forecast: Advanced Biomed, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 10 of 100 as at 1 Aug 2026 — in the weakest quartile.
ADVB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Advanced Biomed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own Advanced Biomed, Inc. — and when they’d sell — is the membership.
ADVB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ADVB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ADVB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Advanced Biomed, Inc. (ADVB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 2.0×
- Price / sales
- —
- Price / book
- 1.2×
- EV / EBITDA
- −3.1×
Cheaper than 69% of US stocks
Cheaper than 66% of US stocks
Cheaper than 76% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 71.3%
- Return on assets
- −21.5%
- Dividend yield
- —
Higher than 95% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ADVB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADVB appears on the weeks it earns a place.
Frequently asked questions about ADVB stock
How does Ticker Nerd's model rank ADVB?
As at 1 Aug 2026, Advanced Biomed, Inc. ranks 10 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
What is the ADVB stock forecast for 2030?
No analyst covering Advanced Biomed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADVB are extrapolating price history, which says nothing about the business.
How has ADVB stock performed over the past year?
Advanced Biomed, Inc. returned -10.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Advanced Biomed, Inc. do?
Advanced Biomed Inc. is a Nevada-incorporated biotechnology holding company specializing in innovative cancer diagnostics and precision oncology solutions.
About Advanced Biomed, Inc.
Advanced Biomed Inc. is a Nevada-incorporated biotechnology holding company specializing in innovative cancer diagnostics and precision oncology solutions. The company operates primarily through subsidiaries in Taiwan and Hong Kong, where it focuses on the research, development, and commercialization of proprietary microfluidic biochip technologies for tumor detection, diagnosis, and treatment applications. Advanced Biomed Inc. has built a microfluidic technology platform that integrates semiconductor fabrication methods with biotechnology to enable advanced circulating tumor cell detection, enrichment, single-cell capture, and analysis from blood samples. Its product portfolio includes devices such as A+Pre, AC-1000, A+CellScan, A+SCDrop, and associated biochips designed to support early cancer screening, diagnostic staging, treatment selection, and monitoring of patient outcomes, with a focus on making assay services rapid and accessible for oncology patients. Headquartered in Tainan, Taiwan, Advanced Biomed Inc. today occupies a niche within the healthcare and medical laboratories sector, serving hospitals, diagnostic centers, and research institutions seeking specialized platforms for precision oncology and advanced biomedical testing.
CEO Mr. Xiaomin Chen Ph.D. · 31 employees · United States · https://www.advanbiomed.com